Original Article
http://dx.doi.org/10.3349/ymj.2013.54.5.1127 pISSN: 0513-5796, eISSN: 1976-2437
Yonsei Med J 54(5):1127-1136, 2013
Reduced Food Intake is the Major Contributor to the Protective Effect of Rimonabant on Islet in Established Obesity-Associated Type 2 Diabetes Sang-Man Jin,1 Bae Jun Oh,2 Suel Lee,2 Jung Mook Choi,3 Soo Jin Yang,4 Sung Woo Park,5 Kwang-Won Kim,1 Jae Hyeon Kim,1 and Cheol-Young Park5 Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Samsung Biomedical Research Institute, Seoul; 3Diabetes Research Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul; 4 Department of Food and Nutrition, Chonnam National University, Gwangju; 5 Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. 1
2
Received: July 25, 2012 Revised: October 1, 2012 Accepted: November 26, 2012 Co-corresponding authors: Dr. Jae Hyeon Kim, Division of Endocrinology and Metabolism, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-1580, Fax: 82-2-3410-3849 E-mail:
[email protected] and Dr. Cheol-Young Park, Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, 29 Saemunan-ro, Jongno-gu, Seoul 110-746, Korea. Tel: 82-2-2001-2440, Fax: 82-2-2001-1588 E-mail:
[email protected] Parts of this study were presented in abstract form at the 3rd Scientific Meeting of the Asian Association for the Study of Diabetes, Beijing, China, July 22-24, 2011. ∙ The authors have no financial conflicts of interest.
Purpose: Although the presence of cannabinoid type 1 (CB1) receptor in islets has been reported, the major contributor to the protective effect of rimonabant on islet morphology is unknown. We determined whether the protective effect of rimonabant on pancreatic islet morphology is valid in established diabetes and also whether any effect was independent of decreased food intake. Materials and Methods: After diabetes was confirmed, Otsuka Long-Evans Tokushima Fatty rats, aged 32 weeks, were treated with rimonabant (30 mg/kg/d, rimonabant group) for 6 weeks. Metabolic profiles and islet morphology of rats treated with rimonabant were compared with those of controls without treatment (control group), a pair-fed control group, and rats treated with rosiglitazone (4 mg/kg/d, rosiglitazone group). Results: Compared to the control group, rats treated with rimonabant exhibited reduced glycated albumin levels (p
